IMPEDIMED LIMITED — Capital/Financing Update 2014

Apr 3, 2014

==> picture [109 x 103] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

4 April 2014

ASX ANNOUNCEMENT

NOTICE CONTAINING INFORMATION REQUIRED UNDER ASX LISTING RULE 3.10.5A

Brisbane, Australia. - Further to the Appendix 3B released on 4 April 2014 for the issue of 45,307,264 fully paid ordinary shares under the placement announced on 28 March 2014 (“ Placement ”), ImpediMed Limited (“ Company ”) provides the following information required under ASX Listing Rule 3.10.5A.

The dilution to existing shareholders as a result of the Placement is as follows:

ASX Listing Rule	Shares	Dilution
Issue under Listing Rule 7.1	27,197,108	12.00%
Issue under Listing Rule 7.1A	18,110,156	7.99%
Total	45,307,264	19.99%

The Company considered that the Placement was the most efficient and expedient method for raising the funds required to achieve its stated objectives. While the Placement was well supported by the Company’s existing institutional shareholders, the Company also considered that the Placement would provide significant benefits by adding new investors to the Company’s shareholder base. The Company has today released a share purchase plan offer booklet to provide eligible existing shareholders with the opportunity to subscribe for additional shares at the same price offered to investors under the Placement (A$0.195 per share).

The Placement was not underwritten.

Canaccord Genuity (Australia) Limited acted as lead manager for the Placement and was paid $441,746 for these services (equivalent to $176,574 for the component of the Placement attributable to the issue of shares under Listing Rule 7.1A).

For further information contact:

Richard Carreon, ImpediMed CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit www.impedimed.com.au

10805715/3